Literature DB >> 31127272

Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.

Christine C Krieger1, Alisa Boutin1, Daesong Jang1, Sarah J Morgan1, J Paul Banga2, George J Kahaly3, Joanna Klubo-Gwiezdzinska4, Susanne Neumann1, Marvin C Gershengorn1.   

Abstract

Endogenously expressed TSH receptors (TSHRs) on orbital fibroblasts of patients with Graves ophthalmopathy (GO) use crosstalk with IGF1 receptors (IGF1R) to synergistically stimulate secretion of hyaluronan (HA), a major component of GO pathology. We previously showed crosstalk occurred upstream of mitogen-activated protein kinase (ERK) phosphorylation. Because other G protein-coupled receptors engage arrestin-β-1 (ARRB1) and ERK, we tested whether ARRB1 was a necessary component of TSHR/IGF1R crosstalk. HA secretion was stimulated by the TSHR-stimulating monoclonal antibodies M22 and KSAb1, or immunoglobulins from patients with GO (GO-Igs). Treatment with M22, as previously shown, resulted in biphasic dose-response stimulation of HA secretion. The high-potency phase was IGF1R dependent, and the low-potency phase was partly IGF1R independent. KSAb1 produced a monophasic dose-response stimulation of HA secretion, whose potency was lowered >20-fold after IGF1R knockdown. ARRB1 knockdown abolished M22's high-potency phase and lowered KSAb1's potency and efficacy. ARRB1 knockdown inhibited GO-Ig stimulation of HA secretion and of ERK phosphorylation. Last, ARRB1 was shown to be necessary for TSHR/IGF1R proximity. In contrast, ARRB2 knockdowns did not show these effects. Thus, TSHR must neighbor IGF1R for crosstalk in GO fibroblasts to occur, and this depends on ARRB1 acting as a scaffold. Similar scaffolding of TSHR and IGF1R by ARRB1 was found in human osteoblast-like cells and human thyrocytes. These findings support a model of TSHR/IGF1R crosstalk that may be a general mechanism for G-protein-coupled receptor/receptor tyrosine kinase crosstalk dependent on ARRB1. Published by Oxford University Press on behalf of the Endocrine Society 2019.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31127272      PMCID: PMC6542485          DOI: 10.1210/en.2019-00055

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  38 in total

Review 1.  Emerging Paradigm of Intracellular Targeting of G Protein-Coupled Receptors.

Authors:  Madhu Chaturvedi; Justin Schilling; Alexandre Beautrait; Michel Bouvier; Jeffrey L Benovic; Arun K Shukla
Journal:  Trends Biochem Sci       Date:  2018-05-04       Impact factor: 13.807

Review 2.  G protein regulation of MAPK networks.

Authors:  Z G Goldsmith; D N Dhanasekaran
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

Review 3.  GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation.

Authors:  Nicolas Delcourt; Joël Bockaert; Philippe Marin
Journal:  Trends Pharmacol Sci       Date:  2007-11-14       Impact factor: 14.819

4.  Thyrotropin and Insulin-Like Growth Factor 1 Receptor Crosstalk Upregulates Sodium-Iodide Symporter Expression in Primary Cultures of Human Thyrocytes.

Authors:  Sarah J Morgan; Susanne Neumann; Bernice Marcus-Samuels; Marvin C Gershengorn
Journal:  Thyroid       Date:  2016-10-18       Impact factor: 6.568

5.  A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody.

Authors:  Seema Kumar; Seethalakshmi Iyer; Hilary Bauer; Michael Coenen; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

6.  Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis.

Authors:  F Peruzzi; M Prisco; M Dews; P Salomoni; E Grassilli; G Romano; B Calabretta; R Baserga
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

7.  Teprotumumab for Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; George J Kahaly; Daniel G Ezra; James C Fleming; Roger A Dailey; Rosa A Tang; Gerald J Harris; Alessandro Antonelli; Mario Salvi; Robert A Goldberg; James W Gigantelli; Steven M Couch; Erin M Shriver; Brent R Hayek; Eric M Hink; Richard M Woodward; Kathleen Gabriel; Guido Magni; Raymond S Douglas
Journal:  N Engl J Med       Date:  2017-05-04       Impact factor: 91.245

Review 8.  Integrating signals from RTKs to ERK/MAPK.

Authors:  M M McKay; D K Morrison
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

9.  β-Arrestin-1 mediates thyrotropin-enhanced osteoblast differentiation.

Authors:  Alisa Boutin; Elena Eliseeva; Marvin C Gershengorn; Susanne Neumann
Journal:  FASEB J       Date:  2014-04-10       Impact factor: 5.191

10.  β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.

Authors:  Huiyuan Zheng; Hongchang Shen; Iulian Oprea; Claire Worrall; Radu Stefanescu; Ada Girnita; Leonard Girnita
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-27       Impact factor: 11.205

View more
  25 in total

1.  Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.

Authors:  Susanne Neumann; Christine C Krieger; Marvin C Gershengorn
Journal:  Eur Thyroid J       Date:  2020-11-02

2.  Modulating TSH Receptor Signaling for Therapeutic Benefit.

Authors:  Gerd Krause; Anja Eckstein; Ralf Schülein
Journal:  Eur Thyroid J       Date:  2020-11-23

3.  TSH stimulation of human thyroglobulin and thyroid peroxidase gene transcription is partially dependent on internalization.

Authors:  Daesong Jang; Elena Eliseeva; Joanna Klubo-Gwiezdzinska; Susanne Neumann; Marvin C Gershengorn
Journal:  Cell Signal       Date:  2021-12-09       Impact factor: 4.315

Review 4.  The risk factors for Graves' ophthalmopathy.

Authors:  Jiamin Cao; Yuhe Su; Zhuokun Chen; Chen Ma; Wei Xiong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-11-17       Impact factor: 3.117

5.  Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.

Authors:  Christine C Krieger; Xiangliang Sui; George J Kahaly; Susanne Neumann; Marvin C Gershengorn
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

6.  Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays.

Authors:  Christine C Krieger; George J Kahaly; Asma Azam; Joanna Klubo-Gwiezdzinska; Susanne Neumann; Marvin C Gershengorn
Journal:  Thyroid       Date:  2021-11-29       Impact factor: 6.568

Review 7.  TSH/IGF1 receptor crosstalk: Mechanism and clinical implications.

Authors:  Christine C Krieger; Susanne Neumann; Marvin C Gershengorn
Journal:  Pharmacol Ther       Date:  2020-02-13       Impact factor: 12.310

Review 8.  Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy.

Authors:  Terry J Smith
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2020-01-31       Impact factor: 4.690

9.  Expression and Role of Thyrotropin Receptors in Proopiomelanocortin-Producing Pituitary Cells.

Authors:  Rafael Maso Prévide; Kai Wang; Kosara Smiljanic; Marija M Janjic; Maria Tereza Nunes; Stanko S Stojilkovic
Journal:  Thyroid       Date:  2021-01-12       Impact factor: 6.568

Review 10.  Insulin-Like Growth Factor Pathway and the Thyroid.

Authors:  Terry J Smith
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-04       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.